马贵清,马如超,陈刚,刘述,苏婧,宋瑞霞,林欣

• 1:兰州大学第二医院(第二临床医学院)心内科

摘要(Abstract)：

急性心肌梗死患者接受经皮冠状动脉介入治疗后若并发急性脑出血，临床管理面临抗栓与止血之间的根本性矛盾。目前尚无专门针对该特殊人群的前瞻性研究或指南推荐，现有实践多借鉴脑卒中合并急性冠状动脉综合征的观察性数据或溶栓相关出血管理经验。在此背景下，建立基于风险分层的动态管理框架尤为迫切。本文旨在系统综述这一特殊临床场景下的管理策略，深入探讨该并发症的病理生理机制、风险评估、治疗决策中的风险权衡、替代性血运重建方案以及多学科协作模式，以期为临床医师提供决策参考，最终改善患者预后。

关键词(KeyWords)： 急性心肌梗死;经皮冠状动脉介入治疗;脑出血;抗栓治疗;管理策略

Abstract:

Keywords:

基金项目(Foundation): 甘肃省自然科学基金专项（26JRRA814）

作者(Author): 马贵清,马如超,陈刚,刘述,苏婧,宋瑞霞,林欣

参考文献(References)：

• [1] Warner ED,Ullah W,Farber J,et al.PCI for acute myocardial infarction in patients with a pre-existing LVAD,does it improve survival?[J].Artif Organs,2023,47(4):761-769.DOI:10.1111/aor.14444.
• [2]Yeh JS,Chen WT,Tomlinson B,et al.Comparing the effectiveness and safety of dual antiplatelet with ticagrelor or clopidogrel in elderly Asian patients with acute myocardial infraction[J].Front Cardiovasc Med,2023,10:1143509.DOI:10.3389/fcvm.2023.1143509.
• [3]Bouhaddoune Y,Benbouchta K,El Ouafi N,et al.Spontaneous subdural hematoma in a patient receiving dual antiplatelet therapy following percutaneous coronary intervention:a case report[J].Ann Med Surg(Lond),2021,71:102941.DOI:10.1016/j.amsu.2021.102941.
• [4]Ibekwe E,Kamdar HA,Strohm T.Cardio-cerebral infarction in left MCA strokes:a case series and literature review[J].Neurol Sci,2022,43(4):2413-2422.DOI:10.1007/s10072-021-05628-x.
• [5]Yokoi H,Oda E,Kaneko K,et al.Duration and clinical outcome of dual antiplatelet therapy after percutaneous coronary intervention:a retrospective cohort study using a medical information database from Japane se hospitals[J].Cardiovasc Interv Ther,2022,37(3):465-474.DOI:10.1007/s12928-021-00833-z.
• [6]Desai A,Escamilla-Ocanas C,Dilip D,et al.Risk of stroke vs.intracerebral hemorrhage in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention:a systematic review and meta-analysis of randomized controlled trials comparing dual vs.triple antithrombotic therapy[J].J Stroke Cereb rovasc Dis,2021,30(4):105654.DOI:10.1016/j.j strokecerebr ovasdis.2021.105654.
• [7]Chua SK,Chen LC,Shyu KG,et al.Antithrombotic strategies in patients with atrial fibrillation following percutaneous coronary intervention:a systemic review and network meta-analysis of randomized controlled trials[J].J Clin Med,2020,9(4):1062.DOI:10.3390/jcm9041062.
• [8]Saglietto A,D'Ascenzo F,Errigo D,et al.Antithrombotic strategies in patients needing oral anticoagulation undergoing percutaneous coronary intervention:a network meta-analy sis[J].Catheter Cardiovasc Interv,2021,97(4):5 81-588.DOI:10.1002/ccd.29192.
• [9]Sheth KN.Spontaneous intracerebral hemorrhage[J].N Engl J Med,2022,3 87(17):1589-1596.DOI:10.105 6/NEJMra2201449.
• [10]Seiffge DJ,Fandler-H??fler S,Du Y,et al.Intracerebral haemorrhagemechanisms,diagno sis and prospects for treatment and prevention[J].Nat Rev Neurol,2024,20(12):708-723.DOI:10.103 8/s41582-024-01035-w.
• [11]Cao X,Wei M,Tang M,et al.Acute myocardial infarction and concomitant acute intracranial hemorrhage:clinical characteristics and outcomes[J].J Investig Med,20 22,70(8):17 1 3-17 1 9.DOI:10.1136/jim-2022-002334.
• [12]Patlolla SH,Sundaragiri PR,Cheungpasitporn W,et al.Intracranial hemorrhage complicating acute myocardial infarction:an 18-year national study of temporal trends,predictors,and outcomes[J].J Clin Med,2020,9(9):2717.DOI:10.3 390/j cm9092717.
• [13]Fujino M,Noguchi T,Torii-Yoshimura T,et al.Outcomes of patients with cerebral microbleeds undergoing percutaneous coronary intervention and dual antiplatelet therapy[J].Heart Vessels,2024,39(9):763-770.DOI:10.1007/s003 80-024-02404-7.
• [14]Charidimou A,Smith EE.Cardiovascular management in asymptomatic(Silent)cerebral microbleeds and suspected cerebral amyloid angiopathy[J].Stroke,2024,55(4):1101-1112.DOI:10.1161/STROKEAHA.123.044167.
• [15]Aronowski J,Zhao X.Molecular pathophysiology of cerebral hemorrhage:secondary brain injury[J].Stroke,2011,42(6):1781-1786.DOI:10.1161/STROKEAHA.110.596718.
• [16]Larsen JB,Hvas AM.Fibrin clot properties in coronary artery disease:new determinants and prognostic markers[J].Pol Arch Intern Med,2021,13 1(11):16113.DOI:10.20452/pamw.16113.
• [17]Murakami T,Sakakura K,Jinnouchi H,et al.Complications related to veno-arterial extracorporeal membrane oxygenation in patients with acute myocardial infarction:VA-E CMO complications in AMI[J].J Cardiol,2022,79(2):170-178.DOI:10.1016/j.jjcc.2021.10.003.
• [18]Bellettini E,De Luca L.Antithrombotic therapy in patients with coronary artery disease and prior stroke[J].J Clin Med,2021,10(9):1923.DOI:10.3390/j cm10091923.
• [19]Nakajima H,Tsuchiya T,Shimizu S,et al.Endovascular therapy for cardiocerebral infarction associated with atrial fibrillation:a case report and literature review[J].Surg Neurol Int,2022,13:479.DOI:10,25259/sni_593_2022.
• [20]中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国急性脑梗死后出血转化诊治共识2019[J].中华神经科杂志,2019,52(4):252-265.DOI:10.3760/cma.j.issn.1006-7876.2019.04.003.
• [21]Hacke W,Kaste M,Fieschi C,et al.Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke.The European Cooperative Acute Stroke Study(ECASS)[J].JAMA,1995,274(13):1017-1025.
• [22] Zhang J,He S,Chen Z,et al.The management and antithrombotic strategies of patients with coronary artery disease and high bleeding risk[J].Curr Cardiol Rep,2023,25(7):669-680.DOI:10.1007/s11886-023-01893-8.
• [23]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.冠心病合并心房颤动患者抗栓管理中国专家共识[J].中华心血管病杂志,2020,48(7):552-564.DOI:10.3760/cma.j.cn112148-20200328-00257.
• [24]Thomas SE,Plumber N,Venkatapathappa P,et al.A review of risk factors and predictors for hemorrhagic transformation in patients with acute ischemic stroke[J].Int J Vasc Med,2021,2021:4244267.DOI:10.115 5/2021/4244267.
• [25]中国医师协会心血管内科医师分会血栓防治专业委员会,中华医学会心血管病学分会介入心脏病学组,中华心血管病杂志编辑委员会.急性冠状动脉综合征特殊人群抗血小板治疗中国专家建议[J].中华心血管病杂志,2018,46(4):255-266.DOI:10.3760/cma.j.issn.0253-3758.2018.04.003.
• [26]Wang HY,Wang Y,Yin D,et al.Percutaneous coronary intervention complexity and risk of adverse events in relation to high bleeding risk among patients receiving drug-eluting stents:insights from a large single-center cohort study[J].J Interv Cardiol,2020,2020:2985435.DOI:10.1155/2020/2985435.
• [27]Zdanyte M,Wrazidlo RW,Kaltenbach S,et al.Predicting l-,3-and 5-year outcomes in patients with coronary artery disease:a comparison of available risk assessment scores[J].Athero sclerosis,2021,318:1-7.DOI:10.1016/j.atherosclero sis.2020.12.007.
• [28]Ono M,Kawashima H,Hara H,et al.External validation of the GRACE risk score 2.0 in the contemporary all-comers GLOBALLEADERS trial[J].Catheter Cardiovasc Interv,2021,98(4):E513-E522.DOI:10.1002/ccd.29772.
• [29]Guo T,Xi Z,Qiu H,et al.Prognostic value of GRACE and CHA_2DS_2-VASc score among patients with atrial fibrillation undergoing percutaneous coronary intervention[J].Ann Med,2021,53(1):2215-2224.DOI:10.1080/07853890.2021.2004321.
• [30]Yamashita D,Saito Y,Sato T,et al.Impact of PARIS and CREDOKyoto thrombotic and bleeding risk scores on clinical outcomes in patients with acute myocardial infarction[J].Circ J,2022,86(4):622-629.DOI:10.1253/circj.CJ-21-05 56.
• [31] Kubota N,Ozaki K,Akiyama T,et al.Correlation between the Japanese version of the high bleeding risk(J-HBR)criteria and the PRECISE-DAPT score,and optimal J-HBR cut-off score to predict major bleeding[J].Circ Rep,2022,4(8):363-370.DOI:10.1253/circrep.CR-22-0059.
• [32]Zhang B,King AJ,Voetsch B,et al.Clinically relevant findings on24-h head CT after acute stroke therapy:the 24-h CT score[J].Int J Stroke,2025,20(2):226-234.DOI:10.1177/17474930241289992.
• [33]Demchuk AM,Dowlatshahi D,Rodriguez-Luna D,et al.Prediction of haematoma growth and outcome in patients with intracerebral haemorrhage using the CT-angiography spot sign(PREDICT):a prospective observational study[J].Lancet Neurol,2012,11(4):307-314.DOI:10.1016/s1474-4422(12)7003 8-8.
• [34] Le LD,Doan BD,Nguyen AT,et al.Concurrent inferior STEMI with third-degree AV block and acute intracranial haemorrhage:how we overcame this clinical challenge-a case report[J].Eur Heart J Case Rep,2025,9(8):ytaf3 85.DOI:10.1093/ehjcr/ytaf385.
• [35]Hong JM,Kim DS,Kim M.Hemorrhagic transformation after ischemic stroke:mechanisms and management[J].Front Neurol,2021,12:703258.DOI:10.3 3 8 9/fneur.2021.703258.
• [36]Gong L,Liu Y,Li J,et al.A narrow therapeutic window of platelet P2Y_(12)reactivity in high-risk Chinese percutaneous coronary intervention patients[J].Peer J,2026,14:e20536.DOI:10.7717/peerj.20536.
• [37] Na K,Qiu M,Ma S,et al.Impact of ticagrelor vs.clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention after risk stratification with the CHA2DS2-VASc score[J].Front Cardiovasc Med,2022,9:808571.DOI:10.3 389/fcvm.2022.808571.
• [38]Carella MC,Carulli E,Loizzi F,et al.Intersections and challenges in the management of acute coronary syndrome and stroke:pathophysiology,treatment dilemmas,and integrated prevention strategies[J].J Clin Med,2025,14(7):2354.DOI:10.3390/jcm14072354.
• [39]Alharthi SY,Alsheikh SA,Almousa DS,et al.Antiplatelet resumption after intracerebral hemorrhage:a systematic review and metaanalysis[J].Diagnostics(Basel),2025,15(14):1780.DOI:10.3 3 90/diagnostics 15141780.
• [40]RESTART Collaboration.Effects of antiplatelet therapy after stroke due to intracereb ral haemo rrhage(RESTART):a rando mised,openlabel trial[J].Lancet,2019,393(10191):2613-2623.DOI:10.1016/s0140-6736(19)30840-2.
• [41] Long B,Brady WJ,Gottlieb M.Fibrinolytic uses in the emergency department:a narrative review[J].Am J Emerg Med,2025,89:85-94.DOI:10.1016/j.ajem.2024.12.007.
• [42]Farrokh S,Nalleballe K,Onteddu S,et al.Bleeding risk with combining antiplatelets and anticoagulants for secondary stroke prevention:a propensity score-matched analysis[J].J Am Heart Assoc,2025,14(16):e042767.DOI:10.1161/JAHA.125.042767.
• [43]Feng X,Liu T.Identification and management strategies for intracoronary high thrombus burden in patients with STEMI:a practical experience and literature review[J].Rev Cardiovasc Med,2025,26(7):37466.DOI:10.31083/RCM37466.
• [44] Pradhan A,Uppal S,Vishwakarma P,et al.Outcomes of patients with acute ST-segment elevation myocardial infarction treated by a prolonged"Deferred"percutaneous coronary intervention strategy[J].World J Cardiol,2025,17(2):99074.DOI:10.4330/wjc.v17.i2.99074.
• [45]中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国脑出血诊治指南(2019)[J].中华神经科杂志,2019,52(12):994-1005.DOI:10.3760/cma.j.issn.1006-7876.20 19.12.003.
• [46]Van de Werf F,Ristic AD,Averkov OV,et al.STREAM-2:half-dose tenecteplase or primary percutaneous coronary intervention in older patients with ST-segment-elevation myocardial infarction:a randomized,open-lab el trial[J].Circulation,2023,148(9):75 3-764.DOI:10.1161/CIRCULATIONAHA.123.064521.
• [47]Li J,Li Y,Zhu P,et al.Remnant cholesterol but not LDL cholesterol is associated with 5-year bleeding following percutaneous coronary intervention[J].iScience,2023,26(10):107666.DOI:10.1016/j.isci.2023.107666.
• [48]Zhou Y,Su X,Liu P,et al.Clinical characteristics and outcomes of hospitalized patients with intracranial hemorrhage after percutaneous coronary intervention[J].Front Cardiovasc Med,2025,12:1424598.DOI:10.3389/fcvm.2025.1424598.
• [49]Shen Y,Ye T.Dual-energy computed tomography(DECT)for diagnosing contrast-induced encephalopathy(CIE)mimicking intracranial hemorrhage(ICH):a rare case[J].Diagnostics(Basel),2025,15(19):2426.DOI:10.33 90/diagno stics15192426.
• [50]Luo L,Hu Q,Yan R,et al.Alpha-asarone ameliorates neuronal injury after ischemic stroke and hemorrhagic transformation by attenuating blood-brain barrier destruction,promoting neurogenesis,and inhibiting neuroinflammation[J].Mol Neurobiol,2025,62(4):5252-5272.DOI:10.1007/s1203 5-024-04596-5.
• [51]Wu YJ,Wu CC,Huang HY,et al.Low-dose prasugrel versus standard-dose ticagrelor in East Asian patients with acute coronary syndrome[J].J Thromb Thrombolysis,2024,57(4):5 37-546.DOI:10.1007/s11239-024-02965-4.
• [52]Hagiwara H,Fukuta H,Niimura T,et al.Comparison of hemorrhagic risk between prasugrel and clopidogrel:a retro spective study using adverse drug event reporting databases[J].Int J Med Sci,2020,17(6):728-73 3.DOI:10.7150/ij ms.43168.
• [53] Abomohsen M,Rifai M,Elgendy MS,et al.Optimal antithrombotic strategies in atrial fibrillation patients undergoing PCI:a network meta-analysis of randomized trials[J].Thromb Res,2026,260:109630.DOI:10.1016/j.thro mres.2026.109630.
• [54]Zoppellaro G,Marchese GM,Squizzato A,et al.Benefit of dual antithrombotic therapy with direct oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention:a systematic review and meta-analysis of randomized clinical trials[J].Intern Emerg Med,2020,15(6):1093-1104.DOI:10.1007/s11739-020-02402-3.
• [55]Zhang Z,Si D,Zhang Q,et al.Prophylactic rivaroxaban therapy for left ventricular thrombus after anterior ST-segment elevation myocardial infarction[J].JACC Cardiovasc Interv,2022,15(8):861-872.DOI:10.1016/j.jcin.2022.01.285.